MX2021013365A - Composiciones utiles para el tratamiento de la enfermedad de pompe. - Google Patents
Composiciones utiles para el tratamiento de la enfermedad de pompe.Info
- Publication number
- MX2021013365A MX2021013365A MX2021013365A MX2021013365A MX2021013365A MX 2021013365 A MX2021013365 A MX 2021013365A MX 2021013365 A MX2021013365 A MX 2021013365A MX 2021013365 A MX2021013365 A MX 2021013365A MX 2021013365 A MX2021013365 A MX 2021013365A
- Authority
- MX
- Mexico
- Prior art keywords
- raav
- pompe disease
- treatment
- compositions useful
- useful
- Prior art date
Links
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 title abstract 3
- 206010053185 Glycogen storage disease type II Diseases 0.000 title abstract 3
- 201000004502 glycogen storage disease II Diseases 0.000 title abstract 3
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840911P | 2019-04-30 | 2019-04-30 | |
| US201962913401P | 2019-10-10 | 2019-10-10 | |
| PCT/US2020/030484 WO2020223356A1 (en) | 2019-04-30 | 2020-04-29 | Compositions useful for treatment of pompe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013365A true MX2021013365A (es) | 2022-01-26 |
Family
ID=73029176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013365A MX2021013365A (es) | 2019-04-30 | 2020-04-29 | Composiciones utiles para el tratamiento de la enfermedad de pompe. |
| MX2021013364A MX2021013364A (es) | 2019-04-30 | 2020-04-29 | Composiciones utiles para el tratamiento de la enfermedad de pompe. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013364A MX2021013364A (es) | 2019-04-30 | 2020-04-29 | Composiciones utiles para el tratamiento de la enfermedad de pompe. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220193261A1 (OSRAM) |
| EP (2) | EP3963063A4 (OSRAM) |
| JP (2) | JP7585233B2 (OSRAM) |
| KR (2) | KR20220008280A (OSRAM) |
| CN (2) | CN114127275A (OSRAM) |
| AU (2) | AU2020266829A1 (OSRAM) |
| BR (2) | BR112021021792A2 (OSRAM) |
| CA (2) | CA3134485A1 (OSRAM) |
| CL (2) | CL2021002755A1 (OSRAM) |
| CO (2) | CO2021016198A2 (OSRAM) |
| IL (2) | IL287523A (OSRAM) |
| MX (2) | MX2021013365A (OSRAM) |
| PH (2) | PH12021552637A1 (OSRAM) |
| SG (2) | SG11202111380VA (OSRAM) |
| TW (1) | TW202100541A (OSRAM) |
| WO (2) | WO2020223356A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3065816T3 (en) | 2017-06-07 | 2026-05-08 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| AU2020361703A1 (en) * | 2019-10-10 | 2022-04-28 | Amicus Therapeutics, Inc. | Variant IGF2 constructs |
| MX2022014255A (es) * | 2020-05-14 | 2022-12-07 | Univ Pennsylvania | Composiciones utiles para el tratamiento de la enfermedad de pompe. |
| JP2023531451A (ja) | 2020-06-17 | 2023-07-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 遺伝子療法患者の治療のための組成物及び方法 |
| CA3237987A1 (en) * | 2021-11-12 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of mucopolysaccharidosis iiia |
| NL2031676B1 (en) * | 2022-04-22 | 2023-11-07 | Univ Erasmus Med Ct Rotterdam | Gene therapy for Pompe Disease |
| WO2024003687A1 (en) * | 2022-06-28 | 2024-01-04 | Pfizer Inc. | Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy |
| WO2024151982A1 (en) * | 2023-01-13 | 2024-07-18 | Amicus Therapeutics, Inc. | Gene therapy constructs for the treatment of pompe disease |
| CN116693633B (zh) * | 2023-02-21 | 2023-12-22 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2025171163A1 (en) * | 2024-02-06 | 2025-08-14 | Duke University | Compositions for and methods of treating lysosomal storage diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5433133B2 (ja) * | 2003-01-22 | 2014-03-05 | デューク・ユニヴァーシティ | リソソームポリペプチドを発現するための改善された構築物 |
| CA2553955C (en) * | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| CA2669347A1 (en) * | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methods for treating pompe disease |
| ES2463665T3 (es) * | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
| ES2629853T3 (es) * | 2008-05-07 | 2017-08-16 | Biomarin Pharmaceutical Inc. | Péptidos de dirección lisosómica y usos de los mismos |
| US8466340B2 (en) * | 2009-02-18 | 2013-06-18 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
| WO2010099342A2 (en) * | 2009-02-25 | 2010-09-02 | Cepheid | Methods of detecting lung cancer |
| EP2475376B1 (en) * | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| DK2643468T3 (en) | 2010-11-22 | 2018-09-24 | Amicus Therapeutics Inc | Hitherto UNKNOWN SIGNAL SEQUENCES TO IMPROVE EXPRESSION AND SECRETARY OF RECOMBINANT ENZYMES AND OTHER PROTEINS |
| WO2012070014A2 (en) * | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
| GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
| TR201802230T4 (tr) * | 2011-05-27 | 2018-03-21 | Amicus Therapeutics Inc | Lizozomal depo hastalıklarının gelişmiş tedavileri için hedefleyici peptitlerin rekombinan lizozomal enzimler üzerine kenetlenmesi için yöntemler. |
| WO2013013019A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Lysosomal polypeptides, methods of making and using |
| JP2017514476A (ja) * | 2014-05-01 | 2017-06-08 | ユニバーシティ・オブ・ワシントン | アデノウイルスベクターを用いたインビボでの遺伝子操作 |
| EP3875593A1 (en) * | 2015-12-11 | 2021-09-08 | California Institute of Technology | Targeting peptides for directing adeno-associated viruses (aavs) |
| SG11201808455VA (en) * | 2016-03-30 | 2018-10-30 | Amicus Therapeutics Inc | Formulations comprising recombinant acid alpha-glucosidase |
| EP3293259A1 (en) * | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293260A1 (en) * | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| PE20191203A1 (es) * | 2016-09-12 | 2019-09-10 | Genethon | Variantes de alfa-glucosidasa acida y usos de las mismas |
| EP3600445A1 (en) * | 2017-03-27 | 2020-02-05 | Vrije Universiteit Brussel | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof |
| JP2018198611A (ja) * | 2018-08-03 | 2018-12-20 | ウニベルシダッド アウトノマ デ バルセロナ | 脂肪組織に形質導入するのに有用なアデノ随伴ウイルスベクター |
-
2020
- 2020-04-29 CA CA3134485A patent/CA3134485A1/en active Pending
- 2020-04-29 MX MX2021013365A patent/MX2021013365A/es unknown
- 2020-04-29 WO PCT/US2020/030484 patent/WO2020223356A1/en not_active Ceased
- 2020-04-29 AU AU2020266829A patent/AU2020266829A1/en not_active Abandoned
- 2020-04-29 JP JP2021565001A patent/JP7585233B2/ja active Active
- 2020-04-29 US US17/606,414 patent/US20220193261A1/en active Pending
- 2020-04-29 MX MX2021013364A patent/MX2021013364A/es unknown
- 2020-04-29 SG SG11202111380VA patent/SG11202111380VA/en unknown
- 2020-04-29 TW TW109114314A patent/TW202100541A/zh unknown
- 2020-04-29 BR BR112021021792A patent/BR112021021792A2/pt unknown
- 2020-04-29 KR KR1020217038223A patent/KR20220008280A/ko not_active Withdrawn
- 2020-04-29 CA CA3134523A patent/CA3134523A1/en active Pending
- 2020-04-29 AU AU2020266552A patent/AU2020266552A1/en not_active Abandoned
- 2020-04-29 PH PH1/2021/552637A patent/PH12021552637A1/en unknown
- 2020-04-29 PH PH1/2021/552638A patent/PH12021552638A1/en unknown
- 2020-04-29 US US17/606,410 patent/US20220193207A1/en not_active Abandoned
- 2020-04-29 BR BR112021021720A patent/BR112021021720A2/pt unknown
- 2020-04-29 CN CN202080048355.1A patent/CN114127275A/zh active Pending
- 2020-04-29 EP EP20799541.6A patent/EP3963063A4/en not_active Withdrawn
- 2020-04-29 EP EP20798851.0A patent/EP3980548A4/en not_active Withdrawn
- 2020-04-29 CN CN202080049015.0A patent/CN114072515A/zh active Pending
- 2020-04-29 JP JP2021564730A patent/JP2022530824A/ja active Pending
- 2020-04-29 KR KR1020217038231A patent/KR20220004696A/ko not_active Withdrawn
- 2020-04-29 WO PCT/US2020/030493 patent/WO2020223362A1/en not_active Ceased
- 2020-04-29 SG SG11202111400TA patent/SG11202111400TA/en unknown
-
2021
- 2021-10-20 CL CL2021002755A patent/CL2021002755A1/es unknown
- 2021-10-20 CL CL2021002754A patent/CL2021002754A1/es unknown
- 2021-10-24 IL IL287523A patent/IL287523A/en unknown
- 2021-10-24 IL IL287522A patent/IL287522A/en unknown
- 2021-11-29 CO CONC2021/0016198A patent/CO2021016198A2/es unknown
- 2021-11-29 CO CONC2021/0016200A patent/CO2021016200A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021016198A2 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
| PE20160188A1 (es) | Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos | |
| CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
| ES2426091T3 (es) | Uso de maquinaria de replicación de AAV para producción de proteína mejorada | |
| CL2020000728A1 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas. | |
| MX2020008932A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| BR112021018776A2 (pt) | Vetores de vírus adenoassociado recombinante | |
| PE20221254A1 (es) | Proteina vp1 modificada aislada de la capside del virus adeno-asociado de serotipo 5 (aav5), capside y vector basado en la misma | |
| EA202090332A1 (ru) | Улучшенная продукция капсида aav в клетках насекомых | |
| SA519402566B1 (ar) | تركيبات نافعة في معالجة ضمور العضل النخاعي | |
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| JP2014012022A5 (OSRAM) | ||
| AR124119A2 (es) | Partículas virales modificadas y usos de estas | |
| EA202091352A1 (ru) | Генотерапия мукополисахаридоза iiib | |
| ES2554752T1 (es) | Sistema de baculovirus para expresar proteínas que forman partículas pseudovirales | |
| García‐Olloqui et al. | Effect of heart ischemia and administration route on biodistribution and transduction efficiency of AAV9 vectors | |
| AR122404A1 (es) | Variantes de cápside y usos de las mismas | |
| CL2022003132A1 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe. | |
| ECSP24013002A (es) | Proteína vp1 de la cápsida aav9 modificada aislada | |
| AR122260A1 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
| EA202192973A1 (ru) | Композиции, полезные для лечения болезни помпе | |
| PE20241345A1 (es) | Proteina vp1 modificada y aislada de la capside del virus adenoasociado del serotipo 5 (aav5), capside y vector basados en esta | |
| RU2022123359A (ru) | Новые капсидные белки аденоассоциированного вируса | |
| AR122251A1 (es) | Composiciones útiles para el tratamiento de la enfermedad de krabbe | |
| AR122261A1 (es) | Composiciones y métodos para el tratamiento de taupatía |